2008 Jun;23(6):844-55
com
S
The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting
Hemolytic Anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage
Avoid pregnancy and use effective contraception during therapy and for 9 months after completion of treatment in female patients and for 6 months in female partners of male patients who are taking ribavirin therapy
This study was conducted to identify the factors contributing to ribavirin-induced anemia
This can make heart disease worse and lead to heart attacks, which can be deadly
13,28,29 WARNING: RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS See full prescribing information for complete boxed warning
Ribavirin-induced haemolytic anaemia is a frequent adverse event leading to drug discontinuation in 36% of the cases in real-life studies, even if this anemia is reversible and dose-dependent
• First report of the use of ribavirin mono-therapy for hepatitis C virus infection
Sickle cell anemia (red blood cell disorder) or Thalassemia major (genetic blood disorder)—Should not be used in patients with these conditions
In previous studies of treatment-naïve patients, anemia requiring dose reduction Avoid pregnancy and use effective contraception during therapy and for 9 months after completion of treatment in female patients and for 6 months in female partners of male patients who are taking ribavirin therapy
The hemolytic anemia can occur suddenly and can result in worsening of cardiac disease, even leading to myocardial infarction
The most common side effect seen with the combination of ribavirin and interferon is a flu-like syndrome consisting of body aches and pains, fever, chills, headache, and malaise
Ribavirin monotherapy, including ribavirin, is not effective for the treatment of chronic hepatitis C virus infection (Boxed Warning)
It has a lot of side effects, so it's usually reserved for people with harder-to-treat chronic hepatitis C infection
Sickle cell anemia (red blood cell disorder) or Thalassemia major (genetic blood disorder)—Should not be used in patients with these conditions
Role of ribavirin in HCV treatment response: now and in the future
clinically significant anemia necessitating transfusion may warrant Ribavirin has some beneficial effects on HFRS patients, whereas treatment of HCPS with this drug remains inconclusive [1,13,14]
We have evaluated the in vitro effects of RBV on erythrocyte adenosine triphosphate (ATP) content and on hexosemonophosphate shunt (HMS)
7 doses of IVIG
It is important that you do not miss or skip a dose of this medicine (ribavirin capsules) during treatment
During treatment, the dose of ribavirin may be changed based on certain test results
No patient developed clinically significant hemolytic anemia or elevations in liver enzymes while receiving inhaled or oral RBV
In these patients, anemia continued to worsen after the 4th week of treatment and did not respond to EPO which was only introduced after anemia appearance
In combination with interferon, it has become part of the standard of care for the treatment of Hepatitis C infection (reviewed in [2,3])
Anemia has been associated with worsening of Heart Problems and in rare cases can cause a Heart Attack and Death
Oral ribavirin has been associated with anemia and extravascular hemolysis
Treatment: Empiric use of ribavirin is not recommended; only patients who meet all
A retrospective descriptive study was conducted involving 19 consecutive critically ill patients during January 27, 2020 to April 18, 2020
A recent study reviewed the predictors of anemia in patients undergoing treatment for
Ribavirin monotherapy, including ribavirin, is not effective for the treatment of chronic hepatitis C virus infection (Boxed Warning)
Clinical experience suggests the utility of ribavirin for the treatment of viral hemorrhagic fevers
Combination therapy is associated with a clinically important
Risk of hemolytic anemia
In addition, ribavirin can cause severe anemia and dose adjustment is required in some patients who develop anemia
Hemolytic Anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage
However, both IFN-α and ribavirin induce hematologic toxicity, such as anemia, neutropenia, and thrombocytopenia, which can compromise treatment adherence and dose maintenance and could, therefore, potentially
Hemolytic anemia has been reported with ribavirin therapy
The hemolytic anemia can occur suddenly and can result in worsening of cardiac disease, even leading to myocardial infarction
Ribavirin is a drug used in combination with interferon for the treatment of chronic hepatitis C
The recommended treatment duration for patients with genotype 2 or 3 is 24 weeks and for other genotypes is 48 weeks
The cost of aerosolized and oral ribavirin therapy is also drastically different